Influenza vaccines in immunosuppressed adults with cancer

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 2, 2018, Pages

  Bitterman, Roni ^a   Eliakim Raz, Noa ^b   Vinograd, Inbal ^c   Zalmanovici Trestioreanu, Anca ^b   Leibovici, Leonard ^b   Paul, Mical ^a  

^a Division of Infectious Diseases   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; IMMUNOLOGICAL ADJUVANT;

ADJUVANT THERAPY; ADULT; ALL CAUSE MORTALITY; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG EFFICACY; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; INFLUENZA; MALIGNANT NEOPLASM; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VACCINATION; BONE MARROW TRANSPLANTATION; CASE CONTROL STUDY; CAUSE OF DEATH; COHORT ANALYSIS; HEMATOLOGIC DISEASE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MORTALITY; NEOPLASM; OBSERVATIONAL STUDY;

ADJUVANTS, IMMUNOLOGIC; ADULT; BONE MARROW TRANSPLANTATION; CASE-CONTROL STUDIES; CAUSE OF DEATH; COHORT STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEOPLASMS; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85041316571     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008983.pub3     Document Type: Review

References (111)

1. Ambati A, Boas LSV, Ljungman P, Testa L, de Oliveira JF, Aoun M, et al. Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study. Bone Marrow Transplantation 2015;50:858-64. 7514586
2. Earle CC. Influenza vaccination in elderly patients with advanced colorectal cancer. Journal of Clinical Oncology 2003;21(6):1161-6. 3380005
3. Machado CM, Cardoso MRA, Da Rocha IF, Boas LSV, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplantation 2005;36:897-900. 3380007
4. Musto P, Carotenuto M. Vaccination against influenza in multiple myeloma. British Journal of Haematology 1997;97(2):504-10. 3380009
5. Natori Y, Humar A, Lipton J, Kim DD, Ashton P, Hoschler K, et al. A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation 2017;52:1016-21. 7514588
6. Vinograd I, Eliakim-Raz N, Farbman L, Baslo R, Taha A, Sakhnini A, et al. Clinical effectiveness of seasonal influenza vaccine among adult cancer patients. Cancer 2013;119(22):4028-35. [10.1002/cncr.28351]3380011
7. Adell C, Bayas JM, Vilella A, Perales M, Vidal J, Bertran MJ, et al. Post-transplantation vaccination of bone-marrow transplant recipients [Vacunacion de pacientes receptores de trasplante de progenitores hematopoyeticos]. Medicina Clinica Journal 2002;119(11):405-9. 3380013
8. Anderson H, Petrie K, Berrisford C, Charlett A, Thatcher N, Zambon M. Seroconversion after influenza vaccination in patients with lung cancer. British Journal of Cancer 1999;80:219-20. 3380015
9. Avetisyan G, Aschan J, Hassan M, Ljungman P. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 2008;86(2):257-63. 3380017
10. Ayoola A, Sukumaran S, Kumar R, Gordon D, Roy A, Vantandoust S, et al. Efficacy of influenza vaccine (FluVax) in patients on chemotherapy (POCT): final data analysis from South Australia. 41st European Society for Medical Oncology Congress, ESMO 2016. 2016. 7514590
11. Baluch A, Humar A, Eurich D, Egli A, Liacini A, Hoschler K, et al. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. American Journal of Transplantation 2013;13(4):1026-33. 7514592
12. Bedognetti D, Zoppoli G, Massucco C, Zupo S, Sertoli MR. Impaired humoral response to influenza vaccine and prolonged B memory cell depletion as a consequence of rituximab-based immunochemotherapy in non-hodgkin lymphoma patients. Journal of Immunotherapy 2009;32(9):992-3. 3380019
13. Bedognetti D, Zoppoli G, Zanardi E, Massucco C, Sertoli MR. Prolonged lack of humoral response to influenza vaccine associated with a persistent depletion of B memory cells in non-hodgkin's lymphoma patients treated with rituximab-containing immunochemotherapy. Clinical Immunology 2010;135:84. 3380021
14. Branagan AR, Duffy E, Boddupall CS, Albrecht RA, Zhang L, Verma R, et al. Fluzone high-dose influenza vaccine with a booster Is associated with low rates of iInfluenza infection in patients with plasma cell disorders. 57th Annual Meeting of the American Society of Hematology, ASH 2015. 2015. 7514594
15. Branagan AR, Duffy E, Parker TL, Seropian S, Foster C, Zhang L, et al. Lower rates of influenza infection following two dose series of high dose vaccination in plasma cell disorders: results of a randomized, double-blind, placebo-assisted clinical trial. 58th Annual Meeting of the American Society of Hematology, ASH 2016. 2016. 7514596
16. Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, et al. Clinical and serologic responses after a two-dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial. Clinical Lymphoma, Myeloma and Leukemia 2017;17(5):296-304. 7514598
17. Brydak LB, Calbecka M. Immunogenicity of influenza vaccine in patients with hemato-oncological disorders. Leukemia and Lymphoma 1999;32(3-4):369-74. 3380023
18. Brydak LB, Guzy J, Starzyk J, Machala M, Gozdz SS. Humoral immune response after vaccination against influenza in patients with breast cancer. Support Care Cancer 2001;9(1):65-8. 3380025
19. Brydak LB, Machala M, Centkowski P, Warzocha K, Bilinski P. Humoral response to hemagglutinin components of influenza vaccine inpatients with non-Hodgkin malignant lymphoma. Vaccine 2006;24:6620-23. 3380027
20. Bucalossi A, Marotta G, Galieni P, Bigazzi C, Valenzin PE, Dispensa E. Immunological response to influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematologica 1995;93(1):56. 3380029
21. Centkowski P, Brydak L, Machala M, Kalinka-Warzocha E, Blasinska-Morawiec M, Federowicz I, et al. Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma. Journal of Clinical Immunology 2007;27(3):339-46. 3380031
22. Chadha MK, Fakih MG, Tian L, Mashtare T, Nesline M. Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients. Journal of Clinical Oncology 2009;27:e20575. 3380033
23. De Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 2011;96(2):307-14. 3380035
24. Dhédin N, Krivine A, Le Corre N, Mallet A, Lioure B, Bay JO, et al. Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients. Vaccine 2014;32(5):585-91. 7514600
25. Engelhard D, Nagler A, Hardan I, Morag A, Aker M, Baciu H, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell depleted and autologous BMT recipients. Bone Marrow Transplant 1993;11(1):1-5. 3380037
26. Feery BJ, Sullivan JR, Hurley TH, Evered MG. Immunization with influenza vaccine in patients with haematological malignant disease. Medical Journal of Australia 1977;1:292-4. 3380039
27. Ganz PA, Shanley JD, Cherry JD. Responses of patients with neoplastic diseases to influenza virus vaccine. Cancer 1978;42:2244-7. 3380041
28. Gribabis DA, Panayiotidis P, Boussiotis VA, Hannoun C, Pangalis GA. Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematologica 1994;91(3):115-8. 3380043
29. Hahn M, Schnitzler P, Schweiger B, Kunz C, Ho AD, Goldschmidt H, et al. Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma. Haematologica 2015;100(7):e285-8. 7514602
30. Hodges GR, Davis JW, Lewis HD Jr, Whittier FC Jr, Siegel CD, Chinn TD, et al. Response to influenza A vaccine among high-risk patients. Southern Medical Journal 1979;72(1):29-32. 3380045
31. Issa NC, Marty FM, Gagne LS, Koo S, Verrill KA, Alvea EP, et al. Seroprotectivetiters against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biological Blood MarrowTransplant 2011;17(3):434-8. 3380047
32. Jamshed S, Walsh EE, Dimitroff LJ, Santelli JS, Falsey AR. Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial. Vaccine 2016;34(5):630-5. 7514604
33. Jo YM, Song JY, Hwang IS, Lee J, Oh SC, Kim JS, et al. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. Journal of Medical Virology 2009;81(4):722-7. 3380049
34. Keam B, Kim MK, Choi Y, Choi SJ, Choe PG, Lee KH, et al. Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles. Cancer 2017;123(5):841-8. 7514606
35. Lachenal F, Sebban C, Duruisseaux M, Biron P, Blay JY, Ghesquières H. Influenza vaccination in patients with haematologic malignancies: analysis of practices in 200 patients in a single center. Bulletin du Cancer 2010;97(4):E33-6. 3380051
36. Lankes HA, Fought AJ, Evens AM, Weisenburger DD, Chiu BC. Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control study. Cancer Causes and Control 2009;20(5):517-23. 3380053
37. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. British Journal of Haematology 2005;130(1):96-8. 3380055
38. Ambati A, Einarsdottir S, Magalhaes I, Poiret T, Bodenstein R, LeBlanc K, et al. Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients. Transplant Infectious Disease 2015;17(3):371-9. 7514608
39. Lo W, Whimbey E, Elting L, Couch R, Cabanillas F, Bodey G. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. European Journal of Clinical Microbiology & Infectious Diseases 1993;12(10):778-82. 3380057
40. Mazza JJ, Yale SH, Arrowood JR, Reynolds CE, Glurich I, Chyou PH, et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clinical Medicine and Research 2005;3(4):214-20. 3380059
41. Mulder SF, Jacobs JFM, Olde Nordkamp MAM, Kremer IK, Mulders PFA. Immunological response to influenza vaccine in cancer patients undergoing treatment with sunitinib or sorafenib. European Journal of Cancer 2009;7:116. 3380061
42. Nakashima K, Aoshima M, Ohfuji S, Suzuki K, Katsurada M, Katsurada N, et al. Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy. Human Vaccines and Immunotherapeutics 2017;13(3):543-50. 7514610
43. Nordoy T, Aaberge IS, Husebekk A, Samdal HH, Steinert S, Melby H, et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Medical Oncology 2002;19(2):71-8. 3380063
44. Ortbals DW, Liebhaber H, Presant CA, Van Amburg AL 3rd, Lee JY. Influenza immunization of adult patients with malignant diseases. Annals of Internal Medicine 1977;87(5):552-7. 3380065
45. Puthillath A, Trump DL, Andrews C, Bir A, Romano K, Wisniewski M, et al. Serological immune responses to influenza vaccine in patients with colorectal cancer. Cancer Chemotherapy and Pharmacology 2011;67(1):111-5. 3380067
46. Rapezzi D, Sticchi L, Racchi O, Mangerini R, Ferraris AM, Gaetani GF. Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. European Journal of Haematology 2003;70(4):225-30. 3380069
47. Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. British Journal of Cancer 2000;82(7):1261-5. 3380071
48. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, et al. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. Journal of Infectious Diseases 2006;194(10):1394-7. 3380073
49. Schafer AI, Churchill WH, Ames P, Weinstein L. The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine. Cancer 1979;43(1):25-30. 3380075
50. Seidel A, Smith D, Yung E, Aquino L, Srivastava T, Pullarkat V, et al. CD154 expression is associated with neutralizing antibody titer levels postinfluenza vaccination in stem cell transplant patients and healthy adults. Biology of Blood and Marrow Transplantation 2011;17(4):524-33. 7514612
51. Shildt RA, Luedke DW, Kasai G, El-Beheri S, Laham MN. Antibody response to influenza immunization in adult patients with malignant disease. Cancer 1979;44(5):1629-35. 3380077
52. Spies CD, Kip M, Lau A, Sander M, Breuer JP, Meyerhoefer J, et al. Influence of vaccination and surgery on HLA-DR expression in patients with upper aerodigestive tract cancer. Journal of International Medical Research 2008;36:296-307. 3380079
53. Spitaleri G, Delmonte A, Toffalorio F, De Pas TM, Gregorc V. Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer. Journal of Thoracic Oncology 2010;5(5):752-4. 3380081
54. Stiver HG, Weinerman BH. Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients. Canadian Medical Association Journal 1978;119(7):733-8. 3380083
55. Sun C, Gao J, Couzens L, Tian X, Farooqui MZ, Eichelberger MC, et al. Seasonal Influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib. JAMA Oncology 2016;2(12):1656-7. 7514614
56. Takata T, Suzumiya J, Ishikawa T, Takamatsu Y, Ikematsu H, Tamura K. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. Journal of Clinical Experimental Hematopathology 2009;49(1):9-13. 3380085
57. Van der Velden AM, Mulder AH, Hartkamp A, Diepersloot RJ, Van Velzen-Blad H, Biesma DH. Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients. European Journal of Internal Medicine 2001;12(5):420-4. 3380087
58. Villa D, Gubbay J, Sutherland DR, Laister R, McGeer A, Cooper C, et al. Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant. Leukemia and Lymphoma 2013;54(7):1387-95. 7514616
59. Wumkes ML, van der Velden AM, Los M, Leys MB, Beeker A, Nijziel MR, et al. Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours. Vaccine 2013;31(52):6177-84. 7514618
60. Xu Y, Methuku N, Coimbatore P, Fitzgerald T, Huang Y, Xiao YY, et al. A prospective study of the immunogenicity of inactivated influenza A (H1N1) 2009 monovalent vaccine in patients who have solid or hematologic malignancies. 48th Annual Meeting of the Infectious Diseases Society of America, 21-24 October 2010; Vancouver, Canada. 2010; Vol. Abstract 5075, posterLB-5013. 3380089
61. Yalçin SS, Kondolot M, Albayrak N, Altaş AB, Karacan Y, Kuşkonmaz B, et al. Serological response to influenza vaccine after hematopoetic stem cell transplantation. Annals of Hematology 2010;89(9):913-8. 3380091
62. Alistair R, Gavin M, Christopher S, Peter H. Influenza vaccination and chemotherapy: a shot in the dark?. Supportive Care in Cancer 2002;10:462-5.
63. Anema A, Mills E, Montaner J, Brownstein JS, Cooper C. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Medicine 2008;9(1):57-61.
64. Angelo SJ, Marshall PS, Chrissoheris MP, Chaves AM. Clinical characteristics associated with poor outcome in patients acutely infected with Influenza A. Connecticut Medicine 2004;68:199-205.
65. Arrowood JR, Hayney MS. Immunization recommendations for adults with cancer. Annals of Pharmacotherapy 2002;36:1219-29.
66. Beck CR, McKenzie BC, Hashim AB, Harris RC, University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. Journal of Infectious Diseases 2012;206(8):1250-9.
67. Black S. Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults. Vaccine 2015;33(Suppl 2):B3-5.
68. Casper C, Englund J, Boeckh M. How I treat influenza in patients with hematologic malignancies. Blood 2010;115(7):1331-42.
69. Centers for Disease Control and Prevention. Cancer prevention and control. Available from: http://www.cdc.gov/cancer/flu/ (accessed 19th October 2017).
70. Centers for Disease Control and Prevention. Flu Vaccination. https://www.cdc.gov/flu/professionals/vaccination/vax-summary.htm (accessed 21st October 2017).
71. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza - United States, 1976-2007. Morbidity and Mortality Weekly Report (MMWR) 2010 Aug 27;59(33):1057-62.
72. Centers for Disease Control and Prevention. Estimated influenza illnesses, medical visits, hospitalizations, and deaths averted by vaccination in the United States. https://www.cdc.gov/flu/about/disease/2015-16.htm (accessed 18th October 2017).
73. Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006;85(5):278-87.
74. Chemaly RF, Vigil KJ, Saad M, Vilar-Compte D, Cornejo-Juarez P, Perez-Jimenez C, et al. A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries: early therapy improves outcomes. Cancer 2012;118(18):4627-33.
75. Cherif H, Höglund M, Pauksens K. Adjuvanted influenza a (H1N1) 2009 vaccine in patients with hematological diseases: good safety and immunogenicity even in chemotherapy-treated patients. European Journal of Haematology 2013;90(5):413-9.
76. Cooksley CD, Avritscher EB, Bekele BN, Rolston KV, Geraci JM, Elting LS. Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer 2005;104:618-28.
77. De Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. Journal of Medical Virology 2000;61(1):94-9.
78. Domnich A, Arata L, Amicizia D, Puig-Barberà J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine 2017;35(4):513-20.
79. Elting LS, Whimbey E, Lo W, Couch R, Andreeff M, Bodey GP. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Supportive Care in Cancer 1995;3(3):198-202.
80. Engelhard D, Mohty B, de la Camara R, Cordonnier C, Ljungman P. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transplant Infectious Disease 2013;15(3):219-32.
81. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports 2009;58:1-52.
82. Glezen WP. Clinical practice. Prevention and treatment of seasonal influenza. New England Journal of Medicine 2008;359:2579-85.
83. Goossen GM, Kremer LCM, Van de Wetering MD. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD006484]
84. Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. Bone Marrow Transplant 2003;32(1):73-7.
85. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta- analysis. Statistics in Medicine 2002;21(11):1539-58.
86. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
87. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
88. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clinical Infectious Diseases 2009;48(6):772-86.
89. Jackson ML, Chung JR, Jackson LA, Phillips CH, Benoit J, Monto AS, et al. Influenza vaccine effectiveness in the United States during the 2015-2016 season. New England Journal of Medicine 2017;377(6):534-43.
90. Kamps BS, Hoffmann C, Preiser W. Influenza report. http://www.influenzareport.com/influenzareport.pdf (accessed 31st December 2006).
91. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infectious Diseases 2009;9:493-504.
92. Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Schunemann HJ. Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews 2013;23(2):81.
93. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biology of Blood and Marrow Transplantation 2001;7:5S-7S.
94. Ljungman P, de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz MJ, et al. Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation, Infectious Complications Subcommittee, Spanish Group of Haematopoietic Stem-cell Transplantation. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica 2011;96(8):1231-5.
95. Machado CM, Boas LS, Mendes AV, Santos MF, Da Rocha IF, Sturaro D, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplantation 2003;31(8):695-700.
96. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews 2014;3:82.
97. Melcher L. Recommendations for influenza and pneumococcal vaccinations in people receiving chemotherapy. Clinical Oncology (Royal College of Radiologists) 2005;17(1):12-5.
98. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clinical Infectious Diseases 2004;39(9):1300-6.
99. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. Newcastle Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm (accessed June 2010).
100. Pedrazzoli P, Baldanti F, Donatelli I, Castrucci MR, Puglisi F, Silvestris N, et al. Italian Society of Medical Oncology. Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM). Annals of Oncology 2014;25(6):1243-7.
101. Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clinical Microbiology Reviews 1998;11(1):1-26.
102. Redelman-Sidi G, Sepkowitz KA, Huang CK, Park S, Stiles J, Eagan J, et al. 2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. Journal of Infection 2010;60(4):257-63.
103. Shehata MA, Karim NA. Influenza vaccination in cancer patients undergoing systemic therapy. Clinical Medicine Insights. Oncology 2014;8:57-64.
104. Scottish Intercollegiate Guideline Network. Search Filters, Methodology. Available from:http://www.sign.ac.uk/methodology/filters.html last modified 16 June 2010; accessed 21st June 2010.
105. Dolin, R. Clinical manifestations and diagnosis of seasonal influenza in adults. www.uptodate.com (accessed 18th October 2017).
106. Vollaard A, Schreuder I, Slok-Raijmakers L, Opstelten W, Rimmelzwaan G, Gelderblom H. Influenza vaccination in adult patients with solid tumours treated with chemotherapy. European Journal of Cancer 2017;76:134-43.
107. World Health Organization. Influenza (Seasonal). Fact sheet N°211; 2016. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/ (accessed 18th October 2017).
108. Wiselka M. Influenza: diagnosis, management, and prophylaxis. BMJ 1994;308(6940):1341-5.
109. Yousuf HM, Englund J, Couch R, Rolston K, Luna M, Goodrich J, et al. Influenza among hospitalized adults with leukemia. Clinical Infectious Diseases 1997;24:1095-9.
110. Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD008983.pub2]
111. Levi-Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines for prevention of influenza-like illness and influenza in immunosuppressed cancer patients. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD008983]